The European Commission announced today that it has approved Moderna’s customized vaccine (Spikevax XBB.1.5) against COVID-19

“This is another important step in the fight against the disease. It is the third adaptation of this vaccine to respond to new variants of COVID-19,” the Commission emphasizes.

The European Medicines Agency (EMA) carried out a rigorous evaluation of the vaccine under the rapid evaluation mechanism.

After this evaluation, the Commission approved the adapted vaccine under a fast-track procedure so that Member States can prepare in time for their vaccination campaigns next autumn and winter.

According to previous recommendations of the EMA and the European Center for Disease Prevention and Control (ECDC), adults and children aged 5 years and older who need vaccination are advised to receive one dose, regardless of their history of vaccination against COVID-19.

Health and Food Safety Commissioner Stella Kyriakides said: “With COVID-19 and seasonal flu circulating this autumn and winter, vaccination remains our most effective tool against both viruses. I encourage those concerned, especially those age 60 and older, people with compromised immune systems and underlying health conditions, to get their booster dose as soon as possible with the most recently updated vaccines that target the variants that are currently circulating. We must all continue to be vigilant and help protect each other.”